Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...
Free White Paper

>>NEW! Download now...
Print

Featured Event...


ChinaBio® Partnering Forum 2012

 May 23-24, 2012 | Suzhou, China

The fourth annual ChinaBio® Partnering Forum is just around the corner. We are expecting more than 700 delegates from all over the world this year. See many of China's leading pharmas including ASK, CTTQ, Fosun, Furen, Hengrui, Hutchison, Luye, Qilu, Reyoung, Simcere, and universities including Fudan, Jiaotong and Tsinghua. Multinationals including Bayer, Astrazeneca, Boehringer Ingleheim, Johnson & Johnson, Life Technologies, Lilly, Lonza, Merck and others will also be in Suzhou seeking strategic alliances and partnerships  making ChinaBio Partnering Forum the event to truly get partnerships started in China.

Bootcamp added on May 22. Find out more.

>> See  www.cbpf2012.com for more information in English or Chinese.

Recent Articles

  J&J in the Hunt for China Pharma Acquisitions (in: Deals & Financings)
May 17, 2012
Johnson & Johnson is actively pursuing M&A in China as a way of keeping its revenue growth at least equal to the general rise in China’s pharmaceutical market – which J&J estimates to be 17%. J&J is especially interested in companies that would add products to its portfolio of mental health drugs and cancer treatments. Unlike some of its big pharma competitors, the company is not branching out into generic drugs as a way to increase China revenues. More details....

Stock Symbol: (NYSE: JNJ)

Share this with colleagues:  

  Baxter Gains SFDA Approval for Recombinant Hemophilia Treatment (in: Trials & Approvals)
May 17, 2012
Baxter International has received approval from the SFDA of its treatment for hemophilia A, a product known as Advate. Advate is a recombinant human coagulation factor VIII for injection used both for control and prevention of bleeding in individuals with hemophilia A. According to Baxter, more than 50,000 people in China have hemophilia A. More details....

Stock Symbol: (NYSE: BAX)

Share this with colleagues:  

  BMS Ups Investment in China R&D and Manufacturing (in: News & Analysis)
May 16, 2012
Announcing two separate strategic China initiatives yesterday, Bristol-Myers Squibb increased its commitment to building its presence in China and its bid for an increased share of the country’s prescription drug market. On the one hand, BMS formed a multi-year strategic partnership with Tsinghua University of Beijing. BMS will underwrite early-stage research to identify new drug targets in oncology and immunoscience. Meanwhile, with a $20 million investment, BMS will expand its manufacturing capacity at its Shanghai site, allowing the company to produce diabetes drugs in China. More details....

Stock Symbol: (NYSE:BMY)

Share this with colleagues:  

  Novozymes Opens Hyaluronic Acid Plant in Tianjin (in: News & Analysis)
May 16, 2012
Novozymes Biopharma, the pharmaceutical subsidiary of Novozymes A/S, a Swedish maker of industrial enzymes, has begun selling hyaluronic acid that is made at its new Tianjin facility. Novozymes’ HA product is manufactured via a Bacillus-based process, while conventionally produced HA is derived from rooster combs or strains of Streptococcus bacteria. In comparison to its competitors’ HA, Novozymes says its HA is less prone to impurities or viral contamination. More details....

Stock Symbols: (NSDQ OMX: Copenhagen: NZYM B)

Share this with colleagues:  

  Partnering Bootcamp Added to ChinaBio® Partnering Forum (in: News & Analysis)
May 15, 2012
For the first time, a Partnering Bootcamp has been added to the annual ChinaBio® Partnering Forum. The Bootcamp, a half-day pre-conference program sponsored by Cooley LLP, will take place on the afternoon of Tuesday, May 22. The ChinaBio® Partnering Forum is hosted by ChinaBio® LLC, a leading consulting firm in Shanghai, and EBD Group, a leading biopharma event organizer. This year’s Partnering Forum will be held May 23-24 in Suzhou, China. More details....

Share this with colleagues:  

  Hisun Pharma to Supply Celsion’s Proprietary Cancer Drug (in: CRO/CMO Services)
May 15, 2012
Zhejiang Hisun Pharma was chosen to be the commercial supplier of ThermoDox®, a clinical-stage liver cancer drug developed by Celsion of the US. ThermoDox® is Celsion's proprietary liposomal encapsulation of doxorubicin. Hisun positioned the agreement as a step toward developing a portfolio of branded generics products. In February of this year, Hisun announced a $245 million JV with Pfizer, a project also devoted to branded generics. More details.....

Stock Symbols: (SHA: 600267) (NSDQ: CLSN) (NYSE: PFE)

Share this with colleagues:  

  IPO of Ningbo David Medical Device Greeted Warmly (in: Deals & Financings)
May 14, 2012
Ningbo David Medical Device Co. completed its IPO on the ChiNext Exchange on May 7, raising 400 million RMB ($63.5 million). The company placed 20 million shares at a price of 20 RMB each, a price/earnings ratio of 30. After rising to a high of 30 RMB, the stock closed today at 26.13 RMB, a return of 31% for the IPO investors. David Medical Device produces infant warmers and products that treat infant jaundice, along with other products that are used in neonatal units. More details....

Stock Symbol: (SHA: 300314)

Share this with colleagues:  

  New China-Australia Research Center to Study TCM (in: News & Analysis)
May 14, 2012
Two China institutions – Shanxi Zhendong Pharmaceutical Company and the Shanxi College of Traditional Chinese Medicine – have banded together with the University of Adelaide in Australia to study the molecular basis of traditional Chinese medicine. Located at the University of Adelaide, the new center’s ultimate goal is to integrate TCM into Western medicine. More details....

Stock Symbol: (SHE: 300158)

Share this with colleagues:  

  Conba Pharma Plans $148 Million Private Placement (in: Deals & Financings)
May 14, 2012
Zhejiang Conba Pharma will raise as much as 925 million RMB ($148 million) via a private placement of 120 million shares at 7.71 RMB each. The funds will be used to boost working capital, according to a company filing. Insiders will purchase the entirety, or at least the majority, of the offering. The new funds add about 15% to Conba's capital base, as the company currently has a market capitalization of $1 billion. More details....

Stock Symbol: (SHA: 600572)

Share this with colleagues:  

  The Week in Review: ChinaBio® Partnering Forum Expecting International Turnout (in: Week in Review)
May 13, 2012
Over 700 industry leaders from the international biotech/pharma community are expected to converge on Suzhou, China for the ChinaBio® Partnering Forum 2012 on May 23–24; Mindray Medical bought a controlling stake in Hangzhou Optcla Medical Instrument, a medical device company specializing in endoscope and related surgical instruments; Zhejiang Hisun announced a strategic alliance with Enzon Pharma of the US to develop therapeutics using Enzon's Customized PEGylation Linker Technology; Zhejiang Huahai Pharma signed an agreement with Breckenridge Pharma allowing Breckenridge exclusive rights to distribute Huahai’s HIV drug Nevirapine in the US; and Shanghai Generon will begin a randomized, multi-center Phase II clinical trial in the US of its biologic treatment for breast cancer. More details…..

Stock Symbols: (NYSE: MR) (NSDQ: ENZN) (SHA: 600267) (SHE: 600521)

Share this with colleagues:  

 
more articles >>
Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events


BioPacific Conference 2012
June 2, 2012
California, USA

  China Forum 2012
  November 11, 2012
Hamburg, Germany

>>More details...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners